# An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

> **NCT06994936** · PHASE1 · COMPLETED · sponsor: **MoonLake Immunotherapeutics AG** · enrollment: 120 (actual)

## Conditions studied

- Relative Bioequivalence

## Interventions

- **DRUG:** Sonelokimab
- **DRUG:** Sonelokimab

## Key facts

- **NCT ID:** NCT06994936
- **Lead sponsor:** MoonLake Immunotherapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-05
- **Primary completion:** 2025-11-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06994936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06994936, "An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06994936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*